Avoiding, Treating & Curing Cancer With the Immune System | Dr. Alex Marson

March 9, 2026·2 hr 27 min·5 clips

Scientists can now genetically engineer T-cells to hunt and destroy cancer cells, a therapy that cured a young girl's leukemia.

A T-cell can be redirected. Dr. Alex Marson explains how a chimeric antigen receptor, designed in a lab rather than found in nature, can be added to immune cells. The goal is targeted destruction. Those altered cells are re-infused into a patient, much like a transfusion, with instructions to search for cancer cells. Huberman keeps the frame clear. He names the larger terrain: immune function, autoimmunity, cancer treatment, and newer tools that may help with childhood and adult cancers. The mechanism never floats away into abstraction. Genes, receptors, and engineered immune behavior become parts of one deliberately built therapeutic system. Viruses do the carrying. Lentivirus and adeno are discussed not as casual threats, but as biological delivery tools whose cell-entry abilities can be used. Huberman pauses for the listener. He notes that hearing about viruses placed into cells and then into people will understandably worry some people. The distinction matters. These viruses are altered so they deliver chosen genetic material, not the disease people may associate with the original virus. Emily Whitehead gives the science a pulse. She was eight when she received an experimental treatment at the University of Pennsylvania in 2012. Her course was hard. She went to the ICU, and people had to manage the immune response and side effects in real time. Then the cancer cells disappeared. The conversation treats that result as a break from older assumptions about engineered immunity. The close turns practical. Huberman points listeners to the Neural Network newsletter for summaries and protocols, then returns to the show's steady gratitude for science.

As heard by us

A grounded look at how immune engineering moved from theory to real cancer treatment.

This episode traces the rise of CAR T-cells, a lab-designed receptor that can be put on T-cells and re-infused into a patient to target cancer.

Read the full review in PlayNext →

Why you'd press play

If you want the logic behind CAR T-cells and why they changed cancer care, start here.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Huberman Lab